Clinical use of rituximab in haematological malignancies

Rituximab is a chimeric human/mouse monoclonal antibody that is approved for the treatment of relapsed and refractory non-Hodgkin's lymphoma (NHL) and in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as first-line therapy for diffuse large B-cell NH...

Descripción completa

Detalles Bibliográficos
Autores principales: Avivi, I, Robinson, S, Goldstone, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394352/
https://www.ncbi.nlm.nih.gov/pubmed/14562003
http://dx.doi.org/10.1038/sj.bjc.6601187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394352/
https://www.ncbi.nlm.nih.gov/pubmed/14562003
http://dx.doi.org/10.1038/sj.bjc.6601187

Ejemplares similares